GlyMab®
Unlocking the therapeutic potential of tumour glycans
Scancell has developed the GlyMab® platform to generate a series of high affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells. Each mAb has high specificity for particular glycan molecules, making them attractive development candidates. In addition to being potential therapies in their own right, the specificity of the anti-glycan mAbs enables their development into a range of antibody-based therapies with differing mechanisms of action.
Targets glycans preferentially expressed on tumours with little expression on normal tissue as the enzymes which attach the glycans are up or down regulated in cancer cells.
Antibody targets are expressed on multiple proteins or lipids in tumours making them attractive for multiple therapeutic modalities like ADC, radioimmunotherapy and cell therapy.
Highly tumour specific and high target affinity. Scancell has unique know how to make high affinity IgG Mabs. Favourable safety profile due restricted expression on normal tissues.
Better specificity on clinically validated glycan targets. Higher specificity with no new glycans to target new cancers to similar expressed on normal cells resulting in potent drugs with less toxicity.
Antibody targets can be adapted to target other cancers. Groundbreaking science leads to validated preclinical results and rapid entry into the clinic.
NK Cell = natural killer cell
ADCC = antibody-dependent cellular cytotoxicity
CDC = complement dependent cytotoxicity
Open to licensing enquiries
commercial@scancell.co.uk
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.
